




PHARMACEUTICAL 2020

Eton Pharmaceuticals Inc.
Rank 245 of 358





RealRate

PHARMACEUTICAL 2020

Eton Pharmaceuticals Inc. Rank 245 of 358



The relative strengths and weaknesses of Eton Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Eton Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is -1.5%, being 38% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	15,009
Cost of Goods Sold	453
Intangible Assets	725
Liabilities, Current	1,963
Liabilities, Non-Current	19
Other Assets	221
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4,540
Other Net Income	0
Other Revenues	1,240
Property and Equipment	1,117
Research and Development	11,555
Selling, General and Administrative Expense	7,552

Output Variable	Value in 1000 USD
Assets	17,072
Liabilities	6,522
Expenses	19,560
Revenues	1,240
Stockholders Equity	10,550
Net Income	-18,320
Comprehensive Net Income	-18,320
Economic Capital Ratio	-1.5%